View in EDS

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.

Saved in:
Bibliographic Details
Title: Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Authors: Schultheis B; Department of Hematology/Oncology, University Bochum, Marien Hospital Herne, Herne;. Electronic address: beate.schultheis@elisabethgruppe.de., Reuter D; Oncoscience AG, Wedel (recently Schenefeld)., Ebert MP; Klinikum Rechts der Isar TU München, München., Siveke J; Klinikum Rechts der Isar TU München, München., Kerkhoff A; University Hospital Münster, Münster., Berdel WE; University Hospital Münster, Münster., Hofheinz R; Department of Hematology and Medical Oncology, University Medical Center Mannheim, Mannheim., Behringer DM; Augusta-Kranken-Anstalt, Bochum., Schmidt WE; St. Josef Hospital, Med. Klinik I, Bochum, Germany., Goker E; Ege University Medical School, Izmir, Turkey., De Dosso S; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Kneba M; Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany., Yalcin S; Hacettepe University Hospital, Ankara, Turkey., Overkamp F; Medical Practice for Oncology and Hematology, Recklinghausen., Schlegel F; St. Antonius Hospital, Eschweiler., Dommach M; Sana-Kliniken, Medizinisches Versorgungszentrum Onkologie, Düsseldorf., Rohrberg R; Gemeinschaftspraxis und Tagesklinik fuer Haematologie, Onkologie und Gastroenterologie, Halle., Steinmetz T; Group Practice Hematology/Oncology Cologne, Cologne., Bulitta M; CRM Biometrics GmbH, Rheinbach, Germany., Strumberg D; Department of Hematology/Oncology, University Bochum, Marien Hospital Herne, Herne.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Oct 01; Vol. 28 (10), pp. 2429-2435.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28961832
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Schultheis+B%22">Schultheis B</searchLink>; Department of Hematology/Oncology, University Bochum, Marien Hospital Herne, Herne;. Electronic address: beate.schultheis@elisabethgruppe.de.<br /><searchLink fieldCode="AU" term="%22Reuter+D%22">Reuter D</searchLink>; Oncoscience AG, Wedel (recently Schenefeld).<br /><searchLink fieldCode="AU" term="%22Ebert+MP%22">Ebert MP</searchLink>; Klinikum Rechts der Isar TU München, München.<br /><searchLink fieldCode="AU" term="%22Siveke+J%22">Siveke J</searchLink>; Klinikum Rechts der Isar TU München, München.<br /><searchLink fieldCode="AU" term="%22Kerkhoff+A%22">Kerkhoff A</searchLink>; University Hospital Münster, Münster.<br /><searchLink fieldCode="AU" term="%22Berdel+WE%22">Berdel WE</searchLink>; University Hospital Münster, Münster.<br /><searchLink fieldCode="AU" term="%22Hofheinz+R%22">Hofheinz R</searchLink>; Department of Hematology and Medical Oncology, University Medical Center Mannheim, Mannheim.<br /><searchLink fieldCode="AU" term="%22Behringer+DM%22">Behringer DM</searchLink>; Augusta-Kranken-Anstalt, Bochum.<br /><searchLink fieldCode="AU" term="%22Schmidt+WE%22">Schmidt WE</searchLink>; St. Josef Hospital, Med. Klinik I, Bochum, Germany.<br /><searchLink fieldCode="AU" term="%22Goker+E%22">Goker E</searchLink>; Ege University Medical School, Izmir, Turkey.<br /><searchLink fieldCode="AU" term="%22De+Dosso+S%22">De Dosso S</searchLink>; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kneba+M%22">Kneba M</searchLink>; Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Yalcin+S%22">Yalcin S</searchLink>; Hacettepe University Hospital, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Overkamp+F%22">Overkamp F</searchLink>; Medical Practice for Oncology and Hematology, Recklinghausen.<br /><searchLink fieldCode="AU" term="%22Schlegel+F%22">Schlegel F</searchLink>; St. Antonius Hospital, Eschweiler.<br /><searchLink fieldCode="AU" term="%22Dommach+M%22">Dommach M</searchLink>; Sana-Kliniken, Medizinisches Versorgungszentrum Onkologie, Düsseldorf.<br /><searchLink fieldCode="AU" term="%22Rohrberg+R%22">Rohrberg R</searchLink>; Gemeinschaftspraxis und Tagesklinik fuer Haematologie, Onkologie und Gastroenterologie, Halle.<br /><searchLink fieldCode="AU" term="%22Steinmetz+T%22">Steinmetz T</searchLink>; Group Practice Hematology/Oncology Cologne, Cologne.<br /><searchLink fieldCode="AU" term="%22Bulitta+M%22">Bulitta M</searchLink>; CRM Biometrics GmbH, Rheinbach, Germany.<br /><searchLink fieldCode="AU" term="%22Strumberg+D%22">Strumberg D</searchLink>; Department of Hematology/Oncology, University Bochum, Marien Hospital Herne, Herne.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2017 Oct 01; Vol. 28 (10), pp. 2429-2435.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28961832
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/annonc/mdx343
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2429
    Titles:
      – TitleFull: Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Schultheis B
      – PersonEntity:
          Name:
            NameFull: Reuter D
      – PersonEntity:
          Name:
            NameFull: Ebert MP
      – PersonEntity:
          Name:
            NameFull: Siveke J
      – PersonEntity:
          Name:
            NameFull: Kerkhoff A
      – PersonEntity:
          Name:
            NameFull: Berdel WE
      – PersonEntity:
          Name:
            NameFull: Hofheinz R
      – PersonEntity:
          Name:
            NameFull: Behringer DM
      – PersonEntity:
          Name:
            NameFull: Schmidt WE
      – PersonEntity:
          Name:
            NameFull: Goker E
      – PersonEntity:
          Name:
            NameFull: De Dosso S
      – PersonEntity:
          Name:
            NameFull: Kneba M
      – PersonEntity:
          Name:
            NameFull: Yalcin S
      – PersonEntity:
          Name:
            NameFull: Overkamp F
      – PersonEntity:
          Name:
            NameFull: Schlegel F
      – PersonEntity:
          Name:
            NameFull: Dommach M
      – PersonEntity:
          Name:
            NameFull: Rohrberg R
      – PersonEntity:
          Name:
            NameFull: Steinmetz T
      – PersonEntity:
          Name:
            NameFull: Bulitta M
      – PersonEntity:
          Name:
            NameFull: Strumberg D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2017 Oct 01
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1